Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01459705
Other study ID # 112226
Secondary ID W81XWH-11-2-0007
Status Completed
Phase N/A
First received October 24, 2011
Last updated November 9, 2015
Start date October 2011
Est. completion date May 2014

Study information

Verified date November 2015
Source National Center for Telehealth and Technology
Contact n/a
Is FDA regulated No
Health authority United States: Federal GovernmentUnited States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

This study is evaluating the efficacy of virtual reality exposure therapy (VRET) by comparing it to prolonged exposure therapy (PE) and a waitlist(WL) group for the treatment of post traumatic stress disorder (PTSD) in active duty (AD) Soldiers with combat-related trauma. The investigators will test the general hypothesis that 10 sessions of VRET or PE will successfully treat PTSD, therapeutically affect levels of physiological arousal, and significantly reduce perceptions of stigma toward seeking behavioral health services.


Description:

The rationale for this study is based on growing evidence demonstrating that VRET is an efficacious treatment for PTSD and holds the potential to improve access to care for Soldiers who would otherwise avoid treatment. Although PE is considered one of the most effective cognitive-behavioral therapies (CBT) for treatments for PTSD, there are reasons why it may not be the most viable option for many Soldiers. First, prolonged exposure requires a level of emotional engagement during exposure to the trauma that many patients are unable to obtain. Second, stigma and concerns about how Soldiers will be perceived by peers and leadership has a dramatic impact on whether a Soldier will seek care. VRET may address these concerns and may also improve treatment outcomes and access to care by augmenting the patient's re-living of the trauma with a sensory-rich environment and moderating stigma perceptions by offering non-traditional treatment that is a preferable option for many Soldiers who are reluctant to seek out traditional talk therapies. Despite its promise as a viable treatment option, few studies have examined VRET for combat-related PTSD and there are no published studies that have compared VRET to PE in the treatment of combat-related PTSD. Positive results may provide new treatment options for all Soldiers, but should prove to be an especially attractive option for Soldiers who either do not respond to, or are reluctant to engage in other established therapies such as PE.


Recruitment information / eligibility

Status Completed
Enrollment 162
Est. completion date May 2014
Est. primary completion date May 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- PTSD diagnosis as assessed by CAPS

- history of deployment in support of Operation Iraqi Freedom/ Operation Enduring Freedom(OIF/OEF)

- non sexually based deployment related trauma

- three or more months since index trauma

- stable on psychotropic medication for 30 days

Exclusion Criteria:

- index trauma in the last three months

- history of schizophrenia, other psychotic or bipolar disorder

- history of organic brain disorder

- suicidal risk or intent or self-mutilating behavior requiring hospitalization in the last 6 months

- ongoing threatening situation

- current drug or alcohol dependence

- history of seizures

- prior history of PE for PTSD

- other current psychotherapy

- physical condition that interferes with proper use of Virtual Reality head mounted display

- history of loss of consciousness since entering active duty service greater than 15 minutes history of schizophrenia, other psychotic or bipolar disorder

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment


Intervention

Behavioral:
Prolonged Exposure Therapy (PE)
Prolonged exposure therapy will consist of 10 treatment sessions lasting 90 - 120 minutes each, with additional between-session homework assignments.
Virtual Reality Exposure Therapy (VRET)
Virtual Reality Exposure Therapy will consist of 10 treatment sessions lasting 90 -120 minutes with additional between-session homework assignments.
Waitlist
This group will refrain from psychotherapy until after the completion of the 5 weeks of study participation

Locations

Country Name City State
United States Womack Clinical Psychology Service Fort Bragg North Carolina

Sponsors (2)

Lead Sponsor Collaborator
National Center for Telehealth and Technology The Geneva Foundation

Country where clinical trial is conducted

United States, 

References & Publications (77)

Ajzen I. From intentions to actions: A theory of planned behavior. In: Kuhl J, Beckman, J, eds. Action-Control: From Cognition to Behavior. Heidelberg: Springer; 1985:11-39.

Anderson P, Rothbaum BO, Hodges LF. Virtual reality exposure in the treatment of social anxiety: Two case reports. Cognitive and Behavioral Practice. 2003;10:240-247.

Aziz MA, Kenford S. Comparability of telephone and face-to-face interviews in assessing patients with posttraumatic stress disorder. J Psychiatr Pract. 2004 Sep;10(5):307-13. — View Citation

Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988 Dec;56(6):893-7. — View Citation

Beck AT, Steer RA, Ball R, Ranieri W. Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. J Pers Assess. 1996 Dec;67(3):588-97. — View Citation

Bisson J, Andrew M. Psychological treatment of post-traumatic stress disorder (PTSD). Cochrane Database Syst Rev. 2005 Apr 18;(2):CD003388. Review. Update in: Cochrane Database Syst Rev. 2007;(3):CD003388. — View Citation

Blake DD, Weathers FW, Nagy LM, Kaloupek DG, Gusman FD, Charney DS, Keane TM. The development of a Clinician-Administered PTSD Scale. J Trauma Stress. 1995 Jan;8(1):75-90. Review. — View Citation

Blanchard EB, Jones-Alexander J, Buckley TC, Forneris CA. Psychometric properties of the PTSD Checklist (PCL). Behav Res Ther. 1996 Aug;34(8):669-73. — View Citation

Bolton EE, Gray MJ, Litz BT. A cross-lagged analysis of the relationship between symptoms of PTSD and retrospective reports of exposure. J Anxiety Disord. 2006;20(7):877-95. Epub 2006 Mar 10. — View Citation

Botella C, Baños RM, Perpiñá C, Villa H, Alcañiz M, Rey A. Virtual reality treatment of claustrophobia: a case report. Behav Res Ther. 1998 Feb;36(2):239-46. — View Citation

Botella C, Perpiñá C, Baños RM, García-Palacios A. Virtual reality: a new clinical setting lab. Stud Health Technol Inform. 1998;58:73-81. Review. — View Citation

Boudewyns P, Hyer L. Physiological response to combat memories and preliminary treatment outcome in Vietnam veteran PTSD patients treated with direct therapeutic exposure. Behavior Therapy. 1990;21 (1):63-87.

Bradley R, Greene J, Russ E, Dutra L, Westen D. A multidimensional meta-analysis of psychotherapy for PTSD. Am J Psychiatry. 2005 Feb;162(2):214-27. Review. Erratum in: Am J Psychiatry. 2005 Apr;162(4):832. Am J Psychiatry. 2006 Feb;163(2):330. — View Citation

Britt TW. The stigma of psychological problems in a work environment: Evidence from the screening of Service Members returning from Bosnia. J of Applied Psych. 2000;30(8):1599-1618

Bryant RA, Moulds ML, Guthrie RM, Dang ST, Nixon RD. Imaginal exposure alone and imaginal exposure with cognitive restructuring in treatment of posttraumatic stress disorder. J Consult Clin Psychol. 2003 Aug;71(4):706-12. — View Citation

Bryant RA. Cognitive behavior therapy of violence-related posttraumatic stress disorder. Aggression and Violent Behavior. 2000;5:79-97.

Cardeña E, Spiegel D. Dissociative reactions to the San Francisco Bay Area earthquake of 1989. Am J Psychiatry. 1993 Mar;150(3):474-8. — View Citation

Carlin AS, Hoffman HG, Weghorst S. Virtual reality and tactile augmentation in the treatment of spider phobia: a case report. Behav Res Ther. 1997 Feb;35(2):153-8. — View Citation

Carlson JG, Chemtob CM, Rusnak K, Hedlund NL, Muraoka MY. Eye movement desensitization and reprocessing (EDMR) treatment for combat-related posttraumatic stress disorder. J Trauma Stress. 1998 Jan;11(1):3-24. — View Citation

Cohen J, Cohen P. Applied Multiple Regression/Correlation Analysis for the Behavioral Sciences. Hillsdale: Lawrence Earlbaum; 1983.

Cohen J. Statistical Power Analysis for the Behavioral Sciences. Hillsdale: Lawrence Earlbaum Associates; 1988.

Delahanty DL, Raimonde AJ, Spoonster E. Initial posttraumatic urinary cortisol levels predict subsequent PTSD symptoms in motor vehicle accident victims. Biol Psychiatry. 2000 Nov 1;48(9):940-7. — View Citation

Difede J, Cukor J, Jayasinghe N, Patt I, Jedel S, Spielman L, Giosan C, Hoffman HG. Virtual reality exposure therapy for the treatment of posttraumatic stress disorder following September 11, 2001. J Clin Psychiatry. 2007 Nov;68(11):1639-47. — View Citation

Difede J, Cukor J, Patt I, Giosan C, Hoffman H. The application of virtual reality to the treatment of PTSD following the WTC attack. Ann N Y Acad Sci. 2006 Jul;1071:500-1. — View Citation

Emmelkamp PM, Krijn M, Hulsbosch AM, de Vries S, Schuemie MJ, van der Mast CA. Virtual reality treatment versus exposure in vivo: a comparative evaluation in acrophobia. Behav Res Ther. 2002 May;40(5):509-16. — View Citation

Foa EB, Hearst-Ikeda D. Emotional Dissociation in Response to Trauma: An Information-Processing Approach. In: Michelson LK, Ray WJ, eds. Handbook of Dissociation: Theoretical and Clinical Perspectives. New York: Plenum Press; 1996:207-222.

Foa EB, Hembree E, Rothbaum BO. Prolonged Exposure Therapy for PTSD: Emotional Processing of Traumatic Experiences. New York: Oxford University Press; 2007.

Foa EB, Kozak MJ. Emotional processing of fear: exposure to corrective information. Psychol Bull. 1986 Jan;99(1):20-35. — View Citation

Foa EB, Meadows EA. Psychosocial treatments for posttraumatic stress disorder: a critical review. Annu Rev Psychol. 1997;48:449-80. Review. — View Citation

Foa EB, Riggs DS, Massie ED, Yarczower M. The impact of fear activation and anger on the efficacy of exposure treatment for PTSD. Behavior Therapy. 1995;26:487-499.

Foa EB,Steketee GS, Rothbaum BO. Behavioral/cognitive conceptualizations of post-traumatic stress disorder. Behavior Therapy. 1989;20:155-176.

Foa EB. Psychosocial treatment of posttraumatic stress disorder. J Clin Psychiatry. 2000;61 Suppl 5:43-8; discussion 49-51. Review. — View Citation

Garcia-Palacios A, Hoffman H, Carlin A, Furness TA 3rd, Botella C. Virtual reality in the treatment of spider phobia: a controlled study. Behav Res Ther. 2002 Sep;40(9):983-93. — View Citation

Gershon J, Zimand E, Lemos R, Rothbaum BO, Hodges L. Use of virtual reality as a distractor for painful procedures in a patient with pediatric cancer: a case study. Cyberpsychol Behav. 2003 Dec;6(6):657-61. — View Citation

Glantz K, Rizzo AA, Graap K. Virtual reality for psychotherapy: Current reality and future possibilities. Psychotherapy: Theory, Research, Practice, Training. 2003;40(1/2):55-67.

Hoge CW, Auchterlonie JL, Milliken CS. Mental health problems, use of mental health services, and attrition from military service after returning from deployment to Iraq or Afghanistan. JAMA. 2006 Mar 1;295(9):1023-32. — View Citation

Hoge CW, Castro CA, Messer SC, McGurk D, Cotting DI, Koffman RL. Combat duty in Iraq and Afghanistan, mental health problems, and barriers to care. N Engl J Med. 2004 Jul 1;351(1):13-22. — View Citation

Jaycox LH, Foa EB, Morral AR. Influence of emotional engagement and habituation on exposure therapy for PTSD. J Consult Clin Psychol. 1998 Feb;66(1):185-92. — View Citation

Keane TM, Kaloupek DG. Imaginal flooding in the treatment of a posttraumatic stress disorder. J Consult Clin Psychol. 1982 Feb;50(1):138-40. — View Citation

Kennedy RS, Lane NE, Berbaum KS, Lilienthal MG. Simulator Sickness Questionnaire: An enhanced method for quantifying simulator sickness. International Journal of Aviation Psychology. 1993;3(3):203-220.

Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB. Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry. 1995 Dec;52(12):1048-60. — View Citation

Koenen KC, Stellman JM, Stellman SD, Sommer JF Jr. Risk factors for course of posttraumatic stress disorder among Vietnam veterans: a 14-year follow-up of American Legionnaires. J Consult Clin Psychol. 2003 Dec;71(6):980-6. — View Citation

Komiya N, Good GE, Sherrod NB. Emotional openness as a predictor of college students' attitudes toward seeking psychological help. J Counsel Psychol. 2000;47(1):138-143.

Koopman C, Classen C, Spiegel D. Predictors of posttraumatic stress symptoms among survivors of the Oakland/Berkeley, Calif., firestorm. Am J Psychiatry. 1994 Jun;151(6):888-94. — View Citation

Larsen DL, Attkisson CC, Hargreaves WA, Nguyen TD. Assessment of client/patient satisfaction: development of a general scale. Eval Program Plann. 1979;2(3):197-207. — View Citation

Lating JM, Everly GS, Jr. Psychophysiological assessment of PTSD. In: Everly, GS, Jr., Lating LM, eds. Psychotraumatology: Key papers and core concepts in post-traumatic stress. New York: Plenum Press; 1995:129-145.

Mackenzie CS, Gekoski WL, Knox VJ. Age, gender, and the underutilization of mental health services: the influence of help-seeking attitudes. Aging Ment Health. 2006 Nov;10(6):574-82. — View Citation

Malloy PF, Fairbank JA, Keane TM. Validation of a multimethod assessment of posttraumatic stress disorders in Vietnam veterans. J Consult Clin Psychol. 1983 Aug;51(4):488-94. — View Citation

Mason J, Southwick S, Yehuda R, Wang S, Riney S, Bremner D, Johnson D, Lubin H, Blake D, Zhou G, et al. Elevation of serum free triiodothyronine, total triiodothyronine, thyroxine-binding globulin, and total thyroxine levels in combat-related posttraumatic stress disorder. Arch Gen Psychiatry. 1994 Aug;51(8):629-41. — View Citation

Morgan CA 3rd, Grillon C, Southwick SM, Davis M, Charney DS. Exaggerated acoustic startle reflex in Gulf War veterans with posttraumatic stress disorder. Am J Psychiatry. 1996 Jan;153(1):64-8. — View Citation

Nishith P, Resick PA. Adherence and competence rating scales for prolonged exposure treatment: Unpublished Rating Scale, University of Missouri-St. Louis; 1994.

Orr SP, Lasko NB, Shalev AY, Pitman RK. Physiologic responses to loud tones in Vietnam veterans with posttraumatic stress disorder. J Abnorm Psychol. 1995 Feb;104(1):75-82. — View Citation

Pitman RK, Orr SP, Altman B, Longpre RE, Poiré RE, Macklin ML, Michaels MJ, Steketee GS. Emotional processing and outcome of imaginal flooding therapy in Vietnam veterans with chronic posttraumatic stress disorder. Compr Psychiatry. 1996 Nov-Dec;37(6):409-18. — View Citation

Pole N. The psychophysiology of posttraumatic stress disorder: a meta-analysis. Psychol Bull. 2007 Sep;133(5):725-46. — View Citation

Pyne JM, Kuc EJ, Schroeder PJ, Fortney JC, Edlund M, Sullivan G. Relationship between perceived stigma and depression severity. J Nerv Ment Dis. 2004 Apr;192(4):278-83. — View Citation

Reger GM, McGee JS, van der Zaag C, Thiebaux M, Galen Buckwalter JG, Rizzo AA. A 3D virtual environment rod and frame test: the reliability and validity of four traditional scoring methods for older adults. J Clin Exp Neuropsychol. 2003 Dec;25(8):1169-77. — View Citation

Resick PA, Nishith P, Weaver TL, Astin MC, Feuer CA. A comparison of cognitive-processing therapy with prolonged exposure and a waiting condition for the treatment of chronic posttraumatic stress disorder in female rape victims. J Consult Clin Psychol. 2002 Aug;70(4):867-79. — View Citation

Rizzo AA, Buckwalter JG, van der Zaag C. Virtual Environment Applications for Neuropsychological Assessment and Rehabilitation. In: Stanney K, ed. Handbook of Virtual Environments. New York: L.A. Earlbaum; 2002:1027-1064.

Rizzo AA, Rothbaum BO, Graap K. Virtual Reality Applications for Combat-Related Posttraumatic Stress Disorder. In: Figley CR, Nash WP, eds. For Those Who Bore the Battle: Combat Stress Injury Theory, Research, and Management. New York: Taylor and Francis Books; 2006.

Rizzo AA, Schultheis MT, Kerns K, Mateer C. Analysis of assets for virtual applications in neuropsychology. Neuropsychological Rehabilitation. 2004;14(1/2):207-239.

Rothbaum BO, Anderson P, Zimand E, Hodges L, Lang D, Wilson J. Virtual reality exposure therapy and standard (in vivo) exposure therapy in the treatment of fear of flying. Behav Ther. 2006 Mar;37(1):80-90. Epub 2006 Feb 24. — View Citation

Rothbaum BO, Hodges L, Alarcon R, Ready D, Shahar F, Graap K, Pair J, Hebert P, Gotz D, Wills B, Baltzell D. Virtual reality exposure therapy for PTSD Vietnam Veterans: a case study. J Trauma Stress. 1999 Apr;12(2):263-71. — View Citation

Rothbaum BO, Hodges L, Anderson PL, Price L, Smith S. Twelve-month follow-up of virtual reality and standard exposure therapies for the fear of flying. J Consult Clin Psychol. 2002 Apr;70(2):428-32. — View Citation

Rothbaum BO, Hodges L, Smith S, Lee JH, Price L. A controlled study of virtual reality exposure therapy for the fear of flying. J Consult Clin Psychol. 2000 Dec;68(6):1020-6. — View Citation

Rothbaum BO, Hodges L, Watson BA, Kessler CD, Opdyke D. Virtual reality exposure therapy in the treatment of fear of flying: a case report. Behav Res Ther. 1996 May-Jun;34(5-6):477-81. — View Citation

Rothbaum BO, Hodges LF, Kooper R, Opdyke D, Williford JS, North M. Effectiveness of computer-generated (virtual reality) graded exposure in the treatment of acrophobia. Am J Psychiatry. 1995 Apr;152(4):626-8. — View Citation

Rothbaum BO, Hodges LF, Ready D, Graap K, Alarcon RD. Virtual reality exposure therapy for Vietnam veterans with posttraumatic stress disorder. J Clin Psychiatry. 2001 Aug;62(8):617-22. — View Citation

Rothbaum BO, Hodges LF. The use of virtual reality exposure in the treatment of anxiety disorders. Behav Modif. 1999 Oct;23(4):507-25. Review. — View Citation

Rothbaum BO, Ruef AM, Litz BT, Han H, Hodges L. Virtual reality exposure therapy of combat-related PTSD: A case study using psychophysiological indicators of outcome. Journal of Cognitive Psychotherapy. 2003;17(2):163-177.

Seal KH, Bertenthal D, Miner CR, Sen S, Marmar C. Bringing the war back home: mental health disorders among 103,788 US veterans returning from Iraq and Afghanistan seen at Department of Veterans Affairs facilities. Arch Intern Med. 2007 Mar 12;167(5):476- — View Citation

Shalev AY, Peri T, Orr SP, Bonne O, Pitman RK. Auditory startle responses in help-seeking trauma survivors. Psychiatry Res. 1997 Mar 3;69(1):1-7. — View Citation

Shalev AY, Sahar T, Freedman S, Peri T, Glick N, Brandes D, Orr SP, Pitman RK. A prospective study of heart rate response following trauma and the subsequent development of posttraumatic stress disorder. Arch Gen Psychiatry. 1998 Jun;55(6):553-9. — View Citation

Sherman JJ. Effects of psychotherapeutic treatments for PTSD: a meta-analysis of controlled clinical trials. J Trauma Stress. 1998 Jul;11(3):413-35. — View Citation

Simms LJ, Watson D, Doebbeling BN. Confirmatory factor analyses of posttraumatic stress symptoms in deployed and nondeployed veterans of the Gulf War. J Abnorm Psychol. 2002 Nov;111(4):637-47. — View Citation

Smith SG, Rothbaum BO, Hodges L. Treatment of fear of flying using virtual reality exposure therapy: A single case study. The Behavior Therapist. 1999;22(8):154-158,160.

Yehuda R, Siever LJ, Teicher MH, Levengood RA, Gerber DK, Schmeidler J, Yang RK. Plasma norepinephrine and 3-methoxy-4-hydroxyphenylglycol concentrations and severity of depression in combat posttraumatic stress disorder and major depressive disorder. Biol Psychiatry. 1998 Jul 1;44(1):56-63. — View Citation

Yehuda R. Post-traumatic stress disorder. N Engl J Med. 2002 Jan 10;346(2):108-14. Review. — View Citation

* Note: There are 77 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary Clinician-Administered PTSD Scale (CAPS) The CAPS is a structured interview that assesses all Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) PTSD criteria in terms of frequency and intensity. We used total scores as the primary outcome. Minimum possible score was 0, maximum possible score was 136. Higher scores indicated higher levels of symptoms. Screening Visit (Day 1) No
Primary Clinician-Administered PTSD Scale (CAPS) The CAPS is a structured interview that assesses all DSM-IV PTSD criteria in terms of frequency and intensity. Scores are computed for Intrusion, Avoidance and Hyperarousal symptom clusters, as well as a Total score.We used total scores as the primary outcome. Minimum possible score was 0, maximum possible score was 136. Higher scores indicated higher levels of symptoms. 2.5 weeks (or after treatment session 5) No
Primary Clinician-Administered PTSD Scale (CAPS) The CAPS is a structured interview that assesses all DSM-IV PTSD criteria in terms of frequency and intensity. Scores are computed for Intrusion, Avoidance and Hyperarousal symptom clusters, as well as a Total score.We used total scores as the primary outcome. Minimum possible score was 0, maximum possible score was 136. Higher scores indicated higher levels of symptoms. 5 weeks (or after treatment session 10) No
Primary Clinician-Administered PTSD Scale (CAPS) The CAPS is a structured interview that assesses all DSM-IV PTSD criteria in terms of frequency and intensity. Scores are computed for Intrusion, Avoidance and Hyperarousal symptom clusters, as well as a Total score.We used total scores as the primary outcome. Minimum possible score was 0, maximum possible score was 136. Higher scores indicated higher levels of symptoms. 12 week follow up No
Primary Clinician-Administered PTSD Scale (CAPS) The CAPS is a structured interview that assesses all DSM-IV PTSD criteria in terms of frequency and intensity. Scores are computed for Intrusion, Avoidance and Hyperarousal symptom clusters, as well as a Total score.We used total scores as the primary outcome. Minimum possible score was 0, maximum possible score was 136. Higher scores indicated higher levels of symptoms. 26 Week follow up No
Secondary PTSD Checklist- Civilian (PCL-C) The PCL-C is a self report measure that evaluates att 17 PTSD criteria using a 5 point Likert scale. Screening Visit (Day 1) No
Secondary Primary Care PTSD Screen (PC-PTSD) The PC-PTSD is a four-item measure designed to screen for PTSD. Screening Visit (Day 1) No
Secondary Beck Depression Inventory-II (BDI-II) This self report measure of depression contains 21 items that are rated on a 4 point scale. Screening Visit(Day 1) Yes
Secondary Inventory of Attitudes Toward Seeking Mental Health Services (IASMHS) The IASMHS is a 24 item assessment of help-seeking attitudes. It includes the following three factors based on components of Ajzen's Theory of Planned Behavior: Psychological Openness, Help-seeking Propensity and Indifference to Stigma. Screening Visit(Day 1) No
Secondary Perceived Stigma Measure (PSS) Stigma will be measured using a 5 question assessment scale. Screening Visit(Day 1) No
Secondary Suicide Risk Assessment Due to the nature of the questions, this is deemed to be of safety nature. Screening Visit(Day 1) No
Secondary Beck Anxiety Inventory (BAI) The BAI is a self report measure consisting of 21 items designed to discriminate anxiety from depression. Screening Visit(Day 1) No
Secondary Behavior and Sympton Identification Scale (BASIS-24) To assess overall psychological pain and gives an indicator of overall wellness. Due to the nature of the questions, this is deemed to be of safety nature. Screening Visit(Day 1) Yes
Secondary Intent to Attend This is a measure to assess the intent to complete study procedures. Screening Visit (Day 1) No
Secondary Subjective Units of Distress (SUDs) Ranging from 1 to 100, Subjective Units of Distress are gathered every 5 mintues during imaginal exposure to determine levels of distress and engagement in the situation. Treatment session 1 (week 1) No
Secondary Side Effects Questionnaire The Side Effects Questionnaire is based on a revised version of the Simulator Sickness Questionnaire (SSQ) that will be used to measure general discomfort in both the VRET and PE conditions of the study. Treatment session 1(week 1) Yes
Secondary BASIS-24 To assess overall psychological pain and gives an indicator of overall wellness. Due to the nature of the questions, this is deemed to be of safety nature. Treatment session 1 (week 1) Yes
Secondary Intent to Attend This is a measure to assess the intent to complete study procedures. Treatment session 1 (week 1) No
Secondary PTSD Checklist (PCL-C) The PCL-C is a self report measure that evaluates att 17 PTSD criteria using a 5 point Likert scale. 2.5 weeks (or after treatment session 5) No
Secondary PTSD Checklist (PCL-C) The PCL-C is a self report measure that evaluates att 17 PTSD criteria using a 5 point Likert scale. 5 weeks (or after treatment session 10) No
Secondary Primary Care PTSD Screen (PC-PTSD) The PC-PTSD is a four-item measure designed to screen for PTSD. 2.5 weeks (or after treatment session 5) No
Secondary PTSD Checklist (PCL-C) The PCL-C is a self report measure that evaluates att 17 PTSD criteria using a 5 point Likert scale. 12 week follow up No
Secondary PTSD Checklist (PCL-C) The PCL-C is a self report measure that evaluates att 17 PTSD criteria using a 5 point Likert scale. 26 week follow up No
Secondary Primary Care PTSD Screen (PC-PTSD) The PC-PTSD is a four-item measure designed to screen for PTSD. 5 weeks (or after treatment session 10) No
Secondary Primary Care PTSD Screen (PC-PTSD) The PC-PTSD is a four-item measure designed to screen for PTSD. 12 Week follow up No
Secondary Primary Care PTSD Screen (PC-PTSD) The PC-PTSD is a four-item measure designed to screen for PTSD. 26 Week follow up No
Secondary Beck Depression Inventory-II (BDI-II) This self report measure of depression contains 21 items that are rated on a 4 point scale. 2.5 weeks (or after treatment session 5) Yes
Secondary Beck Depression Inventory-II (BDI-II) This self report measure of depression contains 21 items that are rated on a 4 point scale. 5 weeks (or after treatment session 10) Yes
Secondary Beck Depression Inventory-II (BDI-II) This self report measure of depression contains 21 items that are rated on a 4 point scale. 12 Week follow up Yes
Secondary Beck Depression Inventory-II (BDI-II) This self report measure of depression contains 21 items that are rated on a 4 point scale. 26 Week follow up Yes
Secondary Inventory of Attitudes Toward Seeking Mental Health Services (IASMHS) The IASMHS is a 24 item assessment of help-seeking attitudes. It includes the following three factors based on components of Ajzen's Theory of Planned Behavior: Psychological Openness, Help-seeking Propensity and Indifference to Stigma. 2.5 weeks (or after treatment session 5) No
Secondary Inventory of Attitudes Toward Seeking Mental Health Services (IASMHS) The IASMHS is a 24 item assessment of help-seeking attitudes. It includes the following three factors based on components of Ajzen's Theory of Planned Behavior: Psychological Openness, Help-seeking Propensity and Indifference to Stigma. 5 weeks (or after treatment session 10) No
Secondary Inventory of Attitudes Toward Seeking Mental Health Services (IASMHS) The IASMHS is a 24 item assessment of help-seeking attitudes. It includes the following three factors based on components of Ajzen's Theory of Planned Behavior: Psychological Openness, Help-seeking Propensity and Indifference to Stigma. 12 Week follow up No
Secondary Inventory of Attitudes Toward Seeking Mental Health Services (IASMHS) The IASMHS is a 24 item assessment of help-seeking attitudes. It includes the following three factors based on components of Ajzen's Theory of Planned Behavior: Psychological Openness, Help-seeking Propensity and Indifference to Stigma. 26 Week follow up No
Secondary Perceived Stigma Measure (PSS) Stigma will be measured using a 5 question assessment scale. 2.5 weeks (or after treatment session 5) No
Secondary Perceived Stigma Measure (PSS) Stigma will be measured using a 5 question assessment scale. 5 weeks (or after treatment session 10) No
Secondary Perceived Stigma Measure (PSS) Stigma will be measured using a 5 question assessment scale. 12 week follow up No
Secondary Perceived Stigma Measure (PSS) Stigma will be measured using a 5 question assessment scale. 26 week follow up No
Secondary Suicide Risk Assessment Due to the nature of the questions, this is deemed to be of safety nature. 2.5 weeks (or after treatment session 5) No
Secondary Suicide Risk Assessment Due to the nature of the questions, this is deemed to be of safety nature. 5 weeks (or after treatment session 10) No
Secondary Suicide Risk Assessment Due to the nature of the questions, this is deemed to be of safety nature. 12 Week follow up No
Secondary Suicide Risk Assessment Due to the nature of the questions, this is deemed to be of safety nature. 26 Week follow up No
Secondary Beck Anxiety Inventory (BAI) The BAI is a self report measure consisting of 21 items designed to discriminate anxiety from depression. 2.5 weeks (or after treatment session 5) No
Secondary Beck Anxiety Inventory (BAI) The BAI is a self report measure consisting of 21 items designed to discriminate anxiety from depression. 5 weeks (or after treatment session 10) No
Secondary Beck Anxiety Inventory (BAI) The BAI is a self report measure consisting of 21 items designed to discriminate anxiety from depression. 12 week follow up No
Secondary Beck Anxiety Inventory (BAI) The BAI is a self report measure consisting of 21 items designed to discriminate anxiety from depression. 26 week follow up No
Secondary BASIS-24 To assess overall psychological pain and gives an indicator of overall wellness. Due to the nature of the questions, this is deemed to be of safety nature. Treatment session 2 (week 1) Yes
Secondary BASIS-24 To assess overall psychological pain and gives an indicator of overall wellness. Due to the nature of the questions, this is deemed to be of safety nature. Treatment session 3 (week 2) Yes
Secondary BASIS-24 To assess overall psychological pain and gives an indicator of overall wellness. Due to the nature of the questions, this is deemed to be of safety nature. Treatment session 4 (week 2) Yes
Secondary BASIS-24 To assess overall psychological pain and gives an indicator of overall wellness. Due to the nature of the questions, this is deemed to be of safety nature. Treatment session 5 (week 2.5) Yes
Secondary BASIS-24 To assess overall psychological pain and gives an indicator of overall wellness. Due to the nature of the questions, this is deemed to be of safety nature. Treatment session 6 (week 3) Yes
Secondary BASIS-24 To assess overall psychological pain and gives an indicator of overall wellness. Due to the nature of the questions, this is deemed to be of safety nature. Treatment session 7 (week 4) Yes
Secondary BASIS-24 To assess overall psychological pain and gives an indicator of overall wellness. Due to the nature of the questions, this is deemed to be of safety nature. Treatment session 8 (week 4) Yes
Secondary BASIS-24 To assess overall psychological pain and gives an indicator of overall wellness. Due to the nature of the questions, this is deemed to be of safety nature. Treatment session 9 (week 5) Yes
Secondary BASIS-24 To assess overall psychological pain and gives an indicator of overall wellness. Due to the nature of the questions, this is deemed to be of safety nature. Treatment session 10 (week 5) Yes
Secondary BASIS-24 To assess overall psychological pain and gives an indicator of overall wellness. Due to the nature of the questions, this is deemed to be of safety nature. 5 weeks (or after treatment session 10) Yes
Secondary BASIS-24 To assess overall psychological pain and gives an indicator of overall wellness. Due to the nature of the questions, this is deemed to be of safety nature. 2.5 weeks (or after treatment session 5) Yes
Secondary BASIS-24 To assess overall psychological pain and gives an indicator of overall wellness. Due to the nature of the questions, this is deemed to be of safety nature. 12 week follow up Yes
Secondary BASIS-24 To assess overall psychological pain and gives an indicator of overall wellness. Due to the nature of the questions, this is deemed to be of safety nature. 26 week follow up Yes
Secondary Subjective Units of Distress (SUDs) Ranging from 1 to 100, Subjective Units of Distress are gathered every 5 mintues during imaginal exposure to determine levels of distress and engagement in the situation. Treatment session 2 (week 1) No
Secondary Subjective Units of Distress (SUDs) Ranging from 1 to 100, Subjective Units of Distress are gathered every 5 mintues during imaginal exposure to determine levels of distress and engagement in the situation. Treatment session 3 (week 2) No
Secondary Subjective Units of Distress (SUDs) Ranging from 1 to 100, Subjective Units of Distress are gathered every 5 mintues during imaginal exposure to determine levels of distress and engagement in the situation. Treatment session 4 (week 2) No
Secondary Subjective Units of Distress (SUDs) Ranging from 1 to 100, Subjective Units of Distress are gathered every 5 mintues during imaginal exposure to determine levels of distress and engagement in the situation. Treatment session 5 (week 2.5) No
Secondary Subjective Units of Distress (SUDs) Ranging from 1 to 100, Subjective Units of Distress are gathered every 5 mintues during imaginal exposure to determine levels of distress and engagement in the situation. Treatment session 6 (week 3) No
Secondary Subjective Units of Distress (SUDs) Ranging from 1 to 100, Subjective Units of Distress are gathered every 5 mintues during imaginal exposure to determine levels of distress and engagement in the situation. Treatment session 7 (week 4) No
Secondary Subjective Units of Distress (SUDs) Ranging from 1 to 100, Subjective Units of Distress are gathered every 5 mintues during imaginal exposure to determine levels of distress and engagement in the situation. Treatment session 8 (week 4) No
Secondary Subjective Units of Distress (SUDs) Ranging from 1 to 100, Subjective Units of Distress are gathered every 5 mintues during imaginal exposure to determine levels of distress and engagement in the situation. Treatment session 9 (week 5) No
Secondary Subjective Units of Distress (SUDs) Ranging from 1 to 100, Subjective Units of Distress are gathered every 5 mintues during imaginal exposure to determine levels of distress and engagement in the situation. Treatment session 10 (week 5) No
Secondary Side Effects Questionnaire The Side Effects Questionnaire is based on a revised version of the Simulator Sickness Questionnaire (SSQ) that will be used to measure general discomfort in both the VRET and PE conditions of the study. Treatment session 2 (week 1) Yes
Secondary Side Effects Questionnaire The Side Effects Questionnaire is based on a revised version of the Simulator Sickness Questionnaire (SSQ) that will be used to measure general discomfort in both the VRET and PE conditions of the study. Treatment session 3 (week 2) Yes
Secondary Side Effects Questionnaire The Side Effects Questionnaire is based on a revised version of the Simulator Sickness Questionnaire (SSQ) that will be used to measure general discomfort in both the VRET and PE conditions of the study. Treatment session 4 (week 2) Yes
Secondary Side Effects Questionnaire The Side Effects Questionnaire is based on a revised version of the Simulator Sickness Questionnaire (SSQ) that will be used to measure general discomfort in both the VRET and PE conditions of the study. Treatment session 5 (week 2.5) Yes
Secondary Side Effects Questionnaire The Side Effects Questionnaire is based on a revised version of the Simulator Sickness Questionnaire (SSQ) that will be used to measure general discomfort in both the VRET and PE conditions of the study. Treatment session 6 (week 3) Yes
Secondary Side Effects Questionnaire The Side Effects Questionnaire is based on a revised version of the Simulator Sickness Questionnaire (SSQ) that will be used to measure general discomfort in both the VRET and PE conditions of the study. Treatment session 7 (week 4) Yes
Secondary Side Effects Questionnaire The Side Effects Questionnaire is based on a revised version of the Simulator Sickness Questionnaire (SSQ) that will be used to measure general discomfort in both the VRET and PE conditions of the study. Treatment session 8 (week 4) Yes
Secondary Side Effects Questionnaire The Side Effects Questionnaire is based on a revised version of the Simulator Sickness Questionnaire (SSQ) that will be used to measure general discomfort in both the VRET and PE conditions of the study. Treatment session 9 (week 5) Yes
Secondary Side Effects Questionnaire The Side Effects Questionnaire is based on a revised version of the Simulator Sickness Questionnaire (SSQ) that will be used to measure general discomfort in both the VRET and PE conditions of the study. Treatment session 10 (week 5) Yes
Secondary Intent to Attend This is a measure to assess the intent to complete study procedures. Treatment session 2 (week 1) No
Secondary Intent to Attend This is a measure to assess the intent to complete study procedures. Treatment session 3 (week 2) No
Secondary Intent to Attend This is a measure to assess the intent to complete study procedures. Treatment session 4 (week 2) No
Secondary Intent to Attend This is a measure to assess the intent to complete study procedures. Treatment session 5 (week 2.5) No
Secondary Intent to Attend This is a measure to assess the intent to complete study procedures. Treatment session 6 (week 3) No
Secondary Intent to Attend This is a measure to assess the intent to complete study procedures. Treatment session 7 (week 4) No
Secondary Intent to Attend This is a measure to assess the intent to complete study procedures. Treatment session 8 (week 4) No
Secondary Intent to Attend This is a measure to assess the intent to complete study procedures. Treatment session 9 (week 5) No
Secondary Intent to Attend This is a measure to assess the intent to complete study procedures. Treatment session 10 (week 5) No
Secondary Intent to Attend This is a measure to assess the intent to complete study procedures. 2.5 weeks (or after treatment session 5) No
See also
  Status Clinical Trial Phase
Recruiting NCT04317820 - Deep Brain Reorienting in Post-traumatic Stress Disorder N/A
Completed NCT05112003 - Translingual Neurostimulation for the Virtual Treatment of Post-Traumatic Stress Disorder: A Feasibility Pilot N/A
Recruiting NCT04518267 - Anger and Psychotrauma: Data From Military and Civilians
Completed NCT02502604 - Cognitive Training Program for Individuals With Depression and Post-Traumatic Stress Disorder N/A
Terminated NCT02234687 - A mGlu2/3 Agonist in the Treatment of PTSD Phase 1
Completed NCT02256566 - Cognitive Training for Mood and Anxiety Disorders N/A
Terminated NCT02520726 - PTSD Prevention Study Examining the Efficacy of Sertraline in Burn Victims Phase 4
Completed NCT02213900 - Preventing Post-Operative Delirium in Patients Undergoing a Pneumonectomy, Esophagectomy or Thoracotomy Phase 4
Completed NCT01738308 - The Effects of Healing Touch on Post Operative Pediatric Patients N/A
Completed NCT01437891 - Sentra AM® and Sentra PM® for Post-traumatic Stress Disorder (PTSD) and Gulf War Fibromyalgia (GWF) N/A
Completed NCT01517711 - Tramadol Extended-Release (ER) for Posttraumatic Stress Disorder (PTSD) Phase 4
Completed NCT01199107 - Maximizing Treatment Outcome and Examining Sleep in Post-traumatic Stress Disorder (PTSD) Phase 3
Completed NCT01998100 - Maximizing Treatment Outcome in Post-Traumatic Stress Disorder (PTSD) Phase 3
Completed NCT01231711 - Improving Quality-of-life and Depressive Symptoms of Combat Veterans Via Internet-based Intervention Phase 1
Completed NCT00348036 - Group Intervention for Interpersonal Trauma N/A
Completed NCT00680524 - Telephone-based Care for OEF/OIF Veterans With PTSD N/A
Completed NCT00838006 - Psychophysiologic Predictors of Post-deployment Mental Health Outcomes N/A
Completed NCT00525226 - Evaluating the Effects of Stress in Pregnancy N/A
Completed NCT00158262 - Effect of Propranolol on Preventing Posttraumatic Stress Disorder Phase 4
Completed NCT00183690 - Prolonged Exposure Therapy Versus Active Psychotherapy in Treating Post-Traumatic Stress Disorder in Adolescents Phase 1